-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The fifth batch of state-organized drug procurement officially started, and the Ningxia Hui Autonomous Region Public Resource Trading Network recently forwarded the Ningxia Medical Insurance Bureau's "Notice on Reporting the Fifth Batch of State-organized Drug Centralized Procurement Product Range Relevant Procurement Data".
It is worth noting that the centralized procurement of injections this time occupies "half of the country", involving 30 varieties, which is significantly more than the sum of the previous collections of injections.
Fengyun Yaotan founder Zhang Tingjie told the "Economic Information Daily" reporter that the fifth batch of Guocai Chuang's products has the largest number and product specifications in the past, and it is expected to affect the market size of 50 billion yuan.
According to data from the Medical Rubik's Cube, there are about 20 varieties with over 1 billion yuan collected this time.
From the perspective of competition, the competition between rivaroxaban oral regular-release dosage forms and esomeprazole injection is fierce, and the number of eligible companies reaches 10 or more.
Unlike before, the fifth batch of national centralized procurement requires that the total demand for drugs from all manufacturers with the same generic name, dosage form, and specification as the fifth batch of national centralized procurement cycle (calculated in one year) be reported in the next centralized procurement cycle.
The fifth batch of state-organized drug procurement officially started, and the Ningxia Hui Autonomous Region Public Resource Trading Network recently forwarded the Ningxia Medical Insurance Bureau's "Notice on Reporting the Fifth Batch of State-organized Drug Centralized Procurement Product Range Relevant Procurement Data".
It is worth noting that the centralized procurement of injections this time occupies "half of the country", involving 30 varieties, which is significantly more than the sum of the previous collections of injections.
Fengyun Yaotan founder Zhang Tingjie told the "Economic Information Daily" reporter that the fifth batch of Guocai Chuang's products has the largest number and product specifications in the past, and it is expected to affect the market size of 50 billion yuan.
According to data from the Medical Rubik's Cube, there are about 20 varieties with over 1 billion yuan collected this time.
From the perspective of competition, the competition between rivaroxaban oral regular-release dosage forms and esomeprazole injection is fierce, and the number of eligible companies reaches 10 or more.
Unlike before, the fifth batch of national centralized procurement requires that the total demand for drugs from all manufacturers with the same generic name, dosage form, and specification as the fifth batch of national centralized procurement cycle (calculated in one year) be reported in the next centralized procurement cycle.
The fifth batch of state-organized drug procurement officially started, and the Ningxia Hui Autonomous Region Public Resource Trading Network recently forwarded the Ningxia Medical Insurance Bureau's "Notice on Reporting the Fifth Batch of State-organized Drug Centralized Procurement Product Range Relevant Procurement Data".
It is worth noting that the centralized procurement of injections this time occupies "half of the country", involving 30 varieties, which is significantly more than the sum of the previous collections of injections.
Fengyun Yaotan founder Zhang Tingjie told the "Economic Information Daily" reporter that the fifth batch of Guocai Chuang's products has the largest number and product specifications in the past, and it is expected to affect the market size of 50 billion yuan.
According to data from the Medical Rubik's Cube, there are about 20 varieties with over 1 billion yuan collected this time.
From the perspective of competition, the competition between rivaroxaban oral regular-release dosage forms and esomeprazole injection is fierce, and the number of eligible companies reaches 10 or more.
Among domestic companies, China Biopharmaceuticals (subsidiary Chia Tai Tianqing, Chia Tai Fenghai and Beijing Tide) involved the most varieties, reaching 10, followed by Qilu and Yangzijiang, with 9 products shortlisted, Kelun, Hausen also has several products involved.
Among multinational companies, AstraZeneca has the most variety this round, reaching six products, and companies such as Pfizer, GlaxoSmithKline, Novartis, and Boehringer Ingelheim also involve more varieties.
Unlike before, the fifth batch of national centralized procurement requires that the total demand for drugs from all manufacturers with the same generic name, dosage form, and specification as the fifth batch of national centralized procurement cycle (calculated in one year) be reported in the next centralized procurement cycle.
Zhang Tingjie said that if the conversion volume of non-over-reviewed drugs is added, and other acid radicals and other dosage forms of products under the same generic name are also reported for volume statistics, the fifth batch of national procurement volume will be beyond imagination and will greatly affect the company’s performance.
Over-evaluation application strategy, original research quotation participation, market structure.
This also means that if the national procurement fails to win the bid, corporate marketing will be more difficult.
(Reporter Liang Qian Zhang Xiaojie)
